JUVMO
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- JUVMO
- Generic name
- TAVAPADON
- Manufacturer
- AbbVie Inc.
- Product type
- HUMAN PRESCRIPTION DRUG
- SPL set ID
- 1ae6df6e-6ca0-420f-bec9-effa7acdd085
- SPL ID
- 1cbfaa3b-d541-4ac3-bf4e-9ab82d8d1b6c
- Version
- 3
- Effective date
- 2026-10-08
- Source export date
- 2026-11-13
- Source partition
- 10
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0010-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/829e43b83940afb8dda22d5287c5b17e57d3fe45d1157678854b4f9b7ad07271/drug-label-0010-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 17:15:13
| Harmonized routes |
|---|
| ORAL |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| application applno | NDA | 220415 | derived:openfda.application_number |
| application number | NDA220415 | openfda.application_number | |
| brand name | JUVMO | openfda.brand_name | |
| generic name | TAVAPADON | openfda.generic_name | |
| manufacturer name | AbbVie Inc. | openfda.manufacturer_name | |
| ndc | package | 0074-6090-40 | openfda.package_ndc |
| ndc | package | 0074-6315-30 | openfda.package_ndc |
| ndc | package | 0074-6210-30 | openfda.package_ndc |
| ndc | package | 0074-6105-30 | openfda.package_ndc |
| ndc | package | 0074-5925-21 | openfda.package_ndc |
| ndc | product | 0074-5925 | openfda.product_ndc |
| ndc | product | 0074-6105 | openfda.product_ndc |
| ndc | product | 0074-6090 | openfda.product_ndc |
| ndc | product | 0074-6315 | openfda.product_ndc |
| ndc | product | 0074-6210 | openfda.product_ndc |
| ndc11 | package | 00074592521 | derived:openfda.package_ndc |
| ndc11 | package | 00074621030 | derived:openfda.package_ndc |
| ndc11 | package | 00074609040 | derived:openfda.package_ndc |
| ndc11 | package | 00074610530 | derived:openfda.package_ndc |
| ndc11 | package | 00074631530 | derived:openfda.package_ndc |
| rxcui | 2754388 | openfda.rxcui | |
| rxcui | 2754371 | openfda.rxcui | |
| rxcui | 2754379 | openfda.rxcui | |
| rxcui | 2754387 | openfda.rxcui | |
| rxcui | 2754389 | openfda.rxcui | |
| rxcui | 2754377 | openfda.rxcui | |
| rxcui | 2754373 | openfda.rxcui | |
| rxcui | 2754385 | openfda.rxcui | |
| rxcui | 2754375 | openfda.rxcui | |
| rxcui | 2754365 | openfda.rxcui | |
| rxcui | 2754383 | openfda.rxcui | |
| rxcui | 2754381 | openfda.rxcui | |
| spl id | 1cbfaa3b-d541-4ac3-bf4e-9ab82d8d1b6c | id | |
| spl set id | 1ae6df6e-6ca0-420f-bec9-effa7acdd085 | set_id | |
| unii | PT4P8MJP8L | openfda.unii |
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
5 WARNINGS AND PRECAUTIONS May cause hypotension/orthostatic hypotension. ( 5.1 ) May cause problems with impulse control or compulsive behaviors. Consider dose reductions or stopping JUVMO. ( 5.2 ) May cause hallucinations and psychotic-like behavior. The risk of hallucinations may be increased when co-administered with strong CYP3A inhibitors during the maintenance phase. ( 5.3 ) May cause dyskinesia or exacerbate pre-existing dyskinesia. ( 5.4 ) 5.1 Hypotension/Orthostatic Hypotension Patients with PD may have an impaired capacity to respond to an orthostatic challenge. In clinical studies and clinical experience, dopaminergic medications appear to impair the systemic regulation of blood pressure, resulting in hypotension and/or orthostatic hypotension, especially during dose escalation. For these reasons, patients with PD being treated with JUVMO should be monitored for signs and symptoms of hypotension/orthostatic hypotension especially during dose escalation, and should be informed of this risk. In Study 1 and Study 2 in patients with PD who were not taking levodopa [see Clinical Studies ( 14.1 )] , orthostatic hypotension was reported in 5% of patients treated with JUVMO compared to 1% of patients who received placebo. Hypotension was reported in 4% of patients treated with JUVMO tablets compared to 1% on placebo. In Study 3 in patients taking JUVMO as adjunctive therapy to fixed dose levodopa [see Clinical Studies ( 14.2 )] , orthostatic hypotension was reported in 8% of patients treated with JUVMO compared to 2% of patients on placebo. Hypotension was reported in 4% of patients treated with JUVMO compared to 0.4% on placebo. 5.2 Impulse Control/Compulsive Behaviors Patients may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges while taking one or more of the medications that increase central dopaminergic tone and are generally used for the treatment of PD, including JUVMO. In some cases, although not all, these urges were reported to have stopped when the dose was reduced or the medication was discontinued. In Study 1 and Study 2, impulse control disorders were reported in 1% of patients treated with JUVMO compared to no patients on placebo. In Study 3, impulse control disorders were reported in 2% of patients treated with JUVMO compared to 1% of patients on placebo. Because patients may not recognize these behaviors as abnormal, it is important for prescribers to ask patients or their caregivers specifically about the development of new or increased gambling urges, sexual urges, uncontrolled spending, binge or compulsive eating, or other urges while being treated with JUVMO. Consider reducing the dose or discontinuing JUVMO if a patient develops such urges. 5.3 Hallucinations and Psychotic-like Behavior Medications for the treatment of PD, including JUVMO, can have effects on thinking and behavior. This abnormal thinking and behavior can consist of one or more of a variety of manifestations including paranoid ideation, delusions, hallucinations, confusion, psychotic-like behavior, symptoms of mania (e.g., insomnia, psychomotor agitation), disorientation, aggressive behavior, agitation, and delirium. In Study 1 and Study 2, hallucination was reported in 3% of patients treated with JUVMO compared to no patients on placebo. In Study 3, when added as an adjunct to a fixed dose of levodopa, hallucination was reported in 7% of patients treated with JUVMO compared to 1% of patients on placebo. Age appears to increase the risk of hallucinations in patients taking JUVMO. In Study 1 and Study 2, among patients 65 years of age and older, hallucination was reported in 4% of patients treated with JUVMO compared to no patients on placebo. In Study 3, among patients 65 years of age and older, hallucination was reported in 9% of patients treated with JUVMO compared to 1% of patients on placebo. The risk of hallucination may be increased when JUVMO is co-administered with strong CYP3A inhibitors during the maintenance phase [see Dosage and Administration ( 2.2 )] . Consider the risks and benefits prior to initiating treatment with JUVMO in patients with a major psychotic disorder because of the risk of exacerbating psychosis. In addition, certain medications used to treat psychosis may exacerbate the symptoms of PD. Consider stopping JUVMO if hallucinations or psychotic-like behaviors occur. 5.4 Dyskinesia JUVMO may cause or exacerbate pre-existing dyskinesia. In Study 1 and Study 2, 0.6% of patients with PD treated with JUVMO reported dyskinesia compared with no patients on placebo. In Study 3, 10.0% of patients treated with JUVMO reported dyskinesia compared to 2% on placebo. Consider decreasing the dosage of JUVMO or other dopaminergic medications if dyskinesia occurs.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The following clinically significant adverse reactions are discussed in greater detail in other sections of the labeling: Hypotension/Orthostatic Hypotension [see Warnings and Precautions ( 5.1 )] Impulse Control/Compulsive Behaviors [see Warnings and Precautions ( 5.2 )] Hallucinations and Psychotic-like Behavior [see Warnings and Precautions ( 5.3 )] Dyskinesia [see Warnings and Pr ec autions ( 5.4 )] Most common adverse reactions (≥ 5%) for JUVMO without concomitant levodopa were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety. ( 6.1 ) Most common adverse reactions (≥ 5%) for JUVMO with concomitant levodopa were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact AbbVie Inc. at 1-800-633-9110 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of JUVMO was evaluated in 1,279 patients with PD who received at least one dose of JUVMO. Of the patients with PD who received JUVMO, 870 were treated for at least 6 months and 630 were treated for at least 1 year. JUVMO without Concomitant L evodopa Study 1 evaluated fixed doses of once daily JUVMO 5 mg (n=177) and JUVMO 15 mg (n=177) compared to placebo (n=175). Study 2 evaluated doses of JUVMO 5 mg to 15 mg unless prevented by intolerance (n=151) compared to placebo (n=153) [see Clinical Studies ( 14.1 )] . In Study 1 and Study 2 combined (n=833 total patients), the most common adverse reactions that occurred in ≥ 5% of patients treated with JUVMO were nausea, headache, dizziness, fatigue, dysgeusia, vomiting, dry mouth, and anxiety. Adverse reactions led to discontinuation of JUVMO in 100 of 505 patients (20%). Of the 100 patients receiving JUVMO who discontinued because of an adverse reaction, 85 (85%) did so during the titration and/or adjustment phases. The most common adverse reactions leading to discontinuation in patients taking JUVMO were nausea, dizziness, headache, and vomiting. Table 4 presents the adverse reactions that occurred in ≥ 3% of patients treated with JUVMO and with a difference of ≥ 2% between the JUVMO and the placebo group in Study 1 and Study 2. Table 4: Adverse Reactions that Occurred in ≥ 3% of Patients with Parkinson’s Disease Treated with JUVMO and ≥ 2% Difference from Placebo in Study 1 and Study 2 (without Concomitant Levodopa) Adverse Reaction JUVMO Placebo ( N=505 ) % ( N=328 ) % Nausea 27 2 Headache a 17 5 Dizziness 14 4 Fatigue b 10 3 Dysgeusia 8 0 Vomiting 7 <1 Dry mouth 5 <1 Anxiety 5 2 Hypotension 4 1 Dyspepsia 4 1 Abnormal dreams 4 <1 Orthostatic hypotension 4 <1 Hallucination c 3 0 Gastroesophageal reflux disease 3 <1 Constipation 3 1 a Headache includes multiple related terms b Fatigue includes asthenia c Hallucination includes multiple related terms JUVMO with Concomitant Levodopa Patients in Study 3 were on a fixed dose of levodopa and were titrated to JUVMO 15 mg once daily unless prevented by intolerance, resulting in maintenance doses between 5 mg and 15 mg (n=251), compared to placebo (n=254). The most common adverse reactions that occurred in ≥ 5% of patients treated with JUVMO were nausea, dyskinesia, dizziness, headache, hallucinations, and orthostatic hypotension. Adverse reactions led to discontinuation of JUVMO in 43 of 251 patients (17%). Of the 43 patients receiving JUVMO who discontinued because of an adverse reaction, 38 (88%) did so during the titration and adjustment phases. The most common adverse reactions leading to discontinuation included nausea, dyskinesia, visual hallucination, and dizziness. Table 5 summarizes the adverse reactions that occurred in ≥ 3% of patients who received JUVMO and with a difference of ≥ 2% between the JUVMO and the placebo groups in Study 3. Table 5: Adverse Reactions that Occurred in ≥ 3% of Patients with Parkinson’s Disease Treated with JUVMO and ≥ 2% Difference from Placebo in Study 3 (with Concomitant Levodopa) Adverse Reaction JUVMO Placebo ( N=251 ) % ( N=254 ) % Nausea 14 4 Dyskinesia 10 2 Dizziness 8 3 Headache a 7 3 Hallucination b 7 1 Orthostatic hypotension 6 1 Hypotension 4 <1 Abdominal pain 3 <1 Asthenia 3 0 a Headache includes multiple related terms b Hallucination includes multiple related terms
adverse reactions table
<table> <caption>Table 4: Adverse Reactions that Occurred in ≥ 3% of Patients with Parkinson’s Disease Treated with JUVMO and ≥ 2% Difference from Placebo in Study 1 and Study 2 (without Concomitant Levodopa)</caption> <col width="410"/> <col width="124"/> <col width="96"/> <tbody> <tr> <td styleCode="Toprule Lrule Rrule " align="center"> <content styleCode="bold">Adverse Reaction</content> </td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">JUVMO</content> </td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">Placebo</content> </td> </tr> <tr> <td styleCode="Lrule " valign="bottom"/> <td styleCode="Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">(</content> <content styleCode="bold">N=505</content> <content styleCode="bold">)</content> <content styleCode="bold">%</content> </td> <td styleCode="Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">(</content> <content styleCode="bold">N=328</content> <content styleCode="bold">)</content> <content styleCode="bold">%</content> </td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Nausea</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">27</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">2</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Headache<sup>a</sup> </td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">17</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">5</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Dizziness</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">14</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Fatigue<sup>b</sup> </td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">10</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Dysgeusia</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">8</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">0</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Vomiting</td> <td styleCode="Toprule Lrule Rrule " align="center">7</td> <td styleCode="Toprule Lrule Rrule " align="center"><1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Dry mouth</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">5</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"><1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Anxiety</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">5</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">2</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Hypotension</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Dyspepsia</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Abnormal dreams</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"><1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Orthostatic hypotension</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"><1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Hallucination<sup>c</sup> </td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">0</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Gastroesophageal reflux disease</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"><1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Constipation</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">1</td> </tr> </tbody> </table>
adverse reactions table
<table> <caption>Table 5: Adverse Reactions that Occurred in ≥ 3% of Patients with Parkinson’s Disease Treated with JUVMO and ≥ 2% Difference from Placebo in Study 3 (with Concomitant Levodopa)</caption> <col width="240"/> <col width="192"/> <col width="192"/> <tbody> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">Adverse Reaction</content> </td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">JUVMO </content> </td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">Placebo</content> <content styleCode="bold"> </content> </td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"/> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">(</content> <content styleCode="bold">N=251</content> <content styleCode="bold">)</content> <content styleCode="bold">%</content> </td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"> <content styleCode="bold">(</content> <content styleCode="bold">N=254</content> <content styleCode="bold">)</content> <content styleCode="bold">%</content> </td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Nausea</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">14</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Dyskinesia</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">10</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">2</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Dizziness</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">8</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Headache<sup>a</sup> </td> <td styleCode="Toprule Lrule Rrule " align="center">7</td> <td styleCode="Toprule Lrule Rrule " align="center">3</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule ">Hallucination<sup>b</sup> </td> <td styleCode="Toprule Lrule Rrule " align="center">7</td> <td styleCode="Toprule Lrule Rrule " align="center">1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Orthostatic hypotension</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">6</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Hypotension</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">4</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"><1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Abdominal pain</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center"><1</td> </tr> <tr> <td styleCode="Toprule Lrule Rrule " valign="bottom">Asthenia</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">3</td> <td styleCode="Toprule Lrule Rrule " valign="bottom" align="center">0</td> </tr> </tbody> </table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.